CANbridge Pharmaceuticals, Inc. announced that long-term follow up data from the Phase 1/2 study of CAN008 plus temozolomide/radiotherapy in newly diagnosed glioblastoma multiforme showed a long-term survival rate of 67% at five years, three years after the trial ended.
